Welcome to our dedicated page for REVIVE THERAPEUTICS news (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on REVIVE THERAPEUTICS stock.
Revive Therapeutics Ltd. develops specialty life sciences programs focused on infectious diseases and medical countermeasures. Company news commonly centers on Bucillamine, including intellectual-property filings, granted patent coverage, and research updates on its potential use in infectious diseases and nerve-agent exposure.
Revive updates also cover work with Defence R&D Canada – Suffield Research Centre, botanical research compounds, molecular hydrogen therapeutic programs, and financing activity. Capital-structure news includes private placements, debt settlement, unit issuances, common share purchase warrants, compensation options, and the use of proceeds for working capital and trade payables.
Revive Therapeutics Ltd. (OTCQB: RVVTF) has entered a research collaboration with PharmaTher Holdings to study the delivery of MDMA using PharmaTher's innovative microneedle patch technology. This collaboration aims to advance the MDMA patch program, potentially addressing mental health disorders such as PTSD, depression, and anxiety. Preliminary research results will be available in Q2-2023 and could lead to further clinical studies. Revive is also advancing its psilocybin programs, including trials for methamphetamine use disorder and developing a biosynthetic version of psilocybin. The microneedle patch offers advantages over oral dosing, enhancing safety and efficacy.
Revive Therapeutics Ltd. (OTCQB: RVVTF) has submitted an updated briefing package to the FDA for its Phase 3 clinical trial of bucillamine as a treatment for COVID-19. This submission includes revised primary and efficacy endpoints, following the FDA's agreement on a Type C meeting request. The trial aims to assess bucillamine's impact on clinical symptoms by comparing patients' conditions at baseline and Day 14. The FDA's response is expected by March 7, 2023. Revive is focusing on outpatient management of mild to moderate COVID-19 cases, with bucillamine potentially mitigating disease burden through its anti-inflammatory and antiviral properties.
Revive Therapeutics Ltd. (OTCQB: RVVTF) announced plans to submit an updated briefing package to the FDA, incorporating data from a University of Toronto study on Bucillamine's effects against COVID-19 Omicron variants. Recently, the FDA granted Revive a Type C meeting to discuss revised protocol endpoints for its Phase 3 clinical trial evaluating Bucillamine for mild to moderate COVID-19. The FDA's written response is expected by March 7, 2023. Notably, Revive does not assert that its product can eliminate or cure COVID-19.
Revive Therapeutics Ltd. (CSE: RVV; OTCQB: RVVTF) has successfully closed a private placement, issuing 28,676,064 units at $0.15 each, yielding gross proceeds of $4,301,409. Each unit consists of one common share and one warrant, allowing the purchase of an additional common share at $0.20 until January 12, 2026. The funds will be used for working capital and clinical development. The offering involved finder’s fees totaling $304,112.75 and 2,294,085 finder warrants. The company's share count now stands at 353,560,075, pending acceptance by the Canadian Securities Exchange.
Revive Therapeutics Ltd. (OTCQB: RVVTF) announced a published study from the University of Toronto indicating that Bucillamine is the most effective FDA-approved antioxidant for disrupting the SARS-CoV-2 spike protein, potentially leading to a new COVID-19 treatment. The FDA has also approved a Type C meeting for Revive to discuss revised protocol endpoints for its Phase 3 clinical trial evaluating Bucillamine's efficacy in treating mild to moderate COVID-19, with a response expected by March 7, 2023.
Revive Therapeutics Ltd. (OTCQB: RVVTF) announced that the FDA has approved its Type C meeting request to discuss revised protocol endpoints for its Phase 3 clinical trial testing Bucillamine for mild to moderate COVID-19. The written response from the FDA is expected by March 7, 2023. Revive emphasizes it does not claim that the drug can cure COVID-19. The company is also developing Psilocybin-based therapeutics and has received FDA orphan drug designation for Cannabidiol aimed at treating autoimmune hepatitis.
Revive Therapeutics Ltd. (RVVTF) has submitted a Type C meeting request to the FDA to discuss revised protocol endpoints for its Phase 3 clinical trial evaluating Bucillamine's efficacy in treating mild to moderate COVID-19. This step is crucial for progressing the trial and the company anticipates a meeting date from the FDA soon. Revive is focused on developing therapeutics for rare disorders and infectious diseases, including severe influenza and COVID-19, while holding several FDA designations aimed at fast-tracking drug development.
Revive Therapeutics is expanding its private placement, aiming to raise between $3 million and $5 million at a price of $0.15 per Unit, which includes one common share and one common share purchase warrant. The offering will now include investors from Quebec and is expected to close in tranches by January 13, 2023. The net proceeds will be utilized for general working capital and clinical development. Finder’s fees up to 8% of gross proceeds will be paid, with the first tranche expected to close by December 30, 2022.
Revive Therapeutics is initiating a private placement to raise between $3 million and $5 million, offering units at $0.15 each. Each unit consists of one common share and one warrant, allowing purchase of an additional share at $0.20 for three years. The offering is expected to close around December 14, 2022, pending regulatory approvals. Proceeds will be used for working capital and clinical development. The company is advancing therapeutic research focusing on infectious diseases and rare disorders, with significant FDA designations for its drug development efforts.
Revive Therapeutics (OTCQB: RVVTF) is set to submit its Type C meeting request to the FDA by mid-December 2022, outlining the development plan for its Phase 3 clinical trial of Bucillamine in treating mild to moderate COVID-19. The submission will include Pre-Dose selection data supporting revised endpoints for the study. Following this, Revive expects a firm date for the FDA meeting to discuss the trial.
The company does not claim that Bucillamine can eliminate or cure COVID-19 at this time.